Literature DB >> 3809589

Quality assurance control in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison.

K A Johansson, J C Horiot, J Van Dam, D Lepinoy, I Sentenac, G Sernbo.   

Abstract

The European Organization for Research on Treatment of Cancer (EORTC) has performed site reviews at 17 institutions participating in clinical trials organized by the Cooperative Group of Radiotherapy. In this paper the dosimetric part of the quality assurance control programme is presented. In a previous paper (part 1) the medical profile of the participating centres was presented. In part 3 an integrated clinical and dosimetric investigation in an anatomical phantom will be presented. The deviations between the absorbed dose values, for specific points along the beam axis in a water phantom, determined by us and reported by the hospitals were within an acceptable level of variation (about +/- 3%) for 85, 70 and 71% of the 60Co gamma, X-ray and electron beams, respectively. In some scanning electron beams, too large deviations were found. The flatness and symmetry of the beams were measured. 73% of the X-ray and 60% of the electron beams were within the acceptable levels of variations. Dosimetric recommendations for institutions participating in EORTC clinical trials are presented.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3809589     DOI: 10.1016/s0167-8140(86)80038-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview.

Authors:  G van Tienhoven; B J Mijnheer; H Bartelink; D G González
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

Review 2.  Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group.

Authors:  Emiel J T Rutgers; Philip Meijnen; Hervé Bonnefoi
Journal:  Breast Cancer Res       Date:  2004-06-16       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.